Hospital
The Nemours Foundation
The Nemours Foundation was paid $104.02M by Medicaid between Jan 2018 and Dec 2024, across 388 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoTHE NEMOURS FOUNDATION
WILMINGTON, DE 19803
WILMINGTON, DE 19803
33aNPI1467505073assigned 01/18/2007
33bProvider typeChildren' s Chronic Disease Hospital
28Total paid$104.02M
24GClaims1,072,163
24DCodes billed388
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 223,912 | $1.33M | |
| 2019 | 208,652 | $9.16M | |
| 2020 | 147,501 | $21.63M | |
| 2021 | 125,540 | $18.79M | |
| 2022 | 132,789 | $20.21M | |
| 2023 | 141,515 | $19.86M | |
| 2024incomplete | 92,254 | $13.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 92,746 | 81,957 | $25.65M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 22,850 | 20,310 | $9.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.8% | 11,541 | 9,210 | $6.08M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 35,285 | 31,390 | $4.28M |
| G0378 | Hospital observation service, per hour | 2.9% | 6,604 | 3,558 | $2.98M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.7% | 39,186 | 10,814 | $2.84M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.3% | 3,120 | 2,886 | $2.38M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 2.1% | 3,729 | 3,416 | $2.19M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.0% | 2,642 | 2,124 | $2.12M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.0% | 365 | 295 | $2.12M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.0% | 22,429 | 7,340 | $2.08M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 26,864 | 8,541 | $1.82M |
376 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.8% | 20,407 | $1.82M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.6% | 1,168 | $1.71M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 18,847 | $1.38M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.3% | 941 | $1.37M |
| 80053 | Comprehensive metabolic panel | 1.3% | 25,227 | $1.36M |
| 93325 | 1.2% | 6,472 | $1.26M | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.0% | 2,355 | $1.06M |
| 93320 | 1.0% | 3,739 | $1.05M | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 991 | $1.02M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,567 | $930K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,734 | $868K |
| 92526 | <1% | 8,242 | $741K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 1,225 | $668K |
| 76770 | <1% | 4,705 | $599K | |
| A0425 | Ground mileage, per statute mile | <1% | 2,941 | $571K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,344 | $527K |
| 92587 | <1% | 8,864 | $521K | |
| 92579 | <1% | 6,655 | $505K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,946 | $496K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,913 | $467K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,317 | $466K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,242 | $466K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,760 | $459K |
| 92567 | <1% | 13,757 | $453K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,821 | $439K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,631 | $420K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,120 | $402K |
| 95782 | <1% | 457 | $396K | |
| 94664 | <1% | 3,907 | $388K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,171 | $385K |
| 72082 | <1% | 4,326 | $337K | |
| 97162 | <1% | 2,229 | $334K | |
| OP370 | <1% | 3,808 | $333K | |
| OP710 | <1% | 4,263 | $328K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 717 | $325K |
| 94010 | <1% | 2,267 | $324K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,622 | $322K |
| 87799 | <1% | 2,375 | $290K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 858 | $286K |
| 36430 | <1% | 1,184 | $272K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 906 | $267K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,896 | $255K |
| 80050 | General health panel | <1% | 1,857 | $243K |
| 94060 | <1% | 1,393 | $240K | |
| A0434 | Specialty care transport (sct) | <1% | 323 | $236K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,470 | $224K |
| 96415 | <1% | 1,828 | $223K | |
| 72170 | <1% | 3,922 | $221K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,288 | $214K |
| 87631 | <1% | 6,218 | $214K | |
| 80061 | Lipid panel | <1% | 5,219 | $213K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,534 | $208K |
| 77073 | <1% | 2,257 | $207K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,340 | $189K |
| 92610 | <1% | 1,029 | $182K | |
| 97161 | <1% | 1,496 | $180K | |
| 74019 | <1% | 4,464 | $175K | |
| 73590 | <1% | 2,406 | $174K | |
| 74018 | <1% | 5,724 | $165K | |
| 84439 | <1% | 4,233 | $164K | |
| 85045 | <1% | 7,463 | $160K | |
| 92552 | <1% | 5,845 | $158K | |
| 92523 | <1% | 885 | $155K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,585 | $149K |
| 94799 | <1% | 2,411 | $147K | |
| 82728 | <1% | 3,391 | $146K | |
| 87077 | <1% | 3,552 | $146K | |
| 93356 | <1% | 583 | $145K | |
| 73080 | <1% | 2,112 | $142K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,271 | $141K |
| 73630 | <1% | 2,945 | $140K | |
| 84100 | <1% | 5,914 | $139K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,406 | $137K |
| 86140 | <1% | 6,632 | $135K | |
| 81001 | <1% | 5,545 | $134K | |
| 85651 | <1% | 6,615 | $132K | |
| 93304 | <1% | 921 | $131K | |
| 73610 | <1% | 2,661 | $130K | |
| 83735 | <1% | 4,537 | $129K | |
| 83516 | <1% | 1,830 | $129K | |
| 86905 | <1% | 407 | $128K | |
| 97116 | <1% | 2,963 | $128K | |
| 82784 | <1% | 3,457 | $127K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,798 | $127K |
| 70360 | <1% | 2,459 | $122K | |
| 80197 | <1% | 1,908 | $118K | |
| 73090 | <1% | 3,335 | $118K | |
| 95816 | <1% | 554 | $117K | |
| 92588 | <1% | 1,016 | $116K | |
| 73110 | <1% | 1,618 | $112K | |
| J3490 | Unclassified drugs | <1% | 36,333 | $108K |
| 81003 | <1% | 4,626 | $107K | |
| 76000 | <1% | 1,025 | $99K | |
| 92555 | <1% | 2,718 | $95K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 802 | $94K |
| 76376 | <1% | 767 | $94K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 522 | $94K |
| 77072 | <1% | 1,759 | $93K | |
| 82977 | <1% | 4,692 | $92K | |
| 73140 | <1% | 1,773 | $91K | |
| 12011 | <1% | 876 | $90K | |
| 93321 | <1% | 1,313 | $88K | |
| 85610 | <1% | 3,377 | $82K | |
| 87497 | <1% | 1,076 | $82K | |
| 92556 | <1% | 1,512 | $79K | |
| 97166 | <1% | 509 | $79K | |
| 87430 | <1% | 3,840 | $78K | |
| 93975 | <1% | 249 | $78K | |
| 83690 | <1% | 2,639 | $77K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,829 | $74K |
| 73130 | <1% | 1,328 | $74K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,303 | $73K |
| 87040 | <1% | 1,526 | $73K | |
| 54161 | <1% | 88 | $73K | |
| 85730 | <1% | 2,738 | $72K | |
| 29515 | <1% | 1,089 | $70K | |
| 86003 | <1% | 1,225 | $69K | |
| 76885 | <1% | 609 | $65K | |
| 92557 | <1% | 865 | $65K | |
| 86900 | <1% | 2,627 | $64K | |
| OP272 | <1% | 754 | $63K | |
| 92550 | <1% | 1,352 | $62K | |
| 92650 | <1% | 346 | $61K | |
| 86850 | <1% | 2,422 | $59K | |
| J2704 | Injection, propofol, 10 mg | <1% | 18,598 | $58K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 336 | $57K |
| 86901 | <1% | 2,560 | $57K | |
| 73562 | <1% | 948 | $55K | |
| 83540 | <1% | 1,965 | $54K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,494 | $53K |
| 82657 | <1% | 701 | $53K | |
| 87070 | <1% | 1,579 | $52K | |
| 42830 | <1% | 225 | $52K | |
| 93976 | <1% | 547 | $47K | |
| 83550 | <1% | 1,179 | $46K | |
| 87186 | <1% | 2,087 | $45K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,184 | $44K |
| 76536 | <1% | 481 | $43K | |
| 80076 | <1% | 1,404 | $42K | |
| 92609 | <1% | 271 | $40K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 15,709 | $40K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 977 | $39K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 3,347 | $39K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,111 | $38K |
| 92582 | <1% | 685 | $37K | |
| 83880 | <1% | 353 | $37K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,527 | $36K |
| 29125 | <1% | 683 | $36K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 960 | $35K |
| 73560 | <1% | 417 | $35K | |
| 97542 | <1% | 481 | $35K | |
| 92553 | <1% | 395 | $35K | |
| 99156 | <1% | 372 | $35K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 21,021 | $34K |
| 97750 | <1% | 126 | $33K | |
| 73521 | <1% | 713 | $33K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,109 | $33K |
| 96409 | <1% | 646 | $33K | |
| 83020 | <1% | 1,200 | $31K | |
| 82570 | <1% | 1,001 | $31K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 208 | $31K |
| 76870 | <1% | 312 | $30K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 483 | $30K |
| 82785 | <1% | 993 | $29K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 62 | $28K |
| 92586 | <1% | 209 | $28K | |
| 73552 | <1% | 619 | $27K | |
| 93308 | <1% | 278 | $26K | |
| 92583 | <1% | 1,685 | $26K | |
| 83970 | <1% | 578 | $26K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 110 | $26K |
| 95812 | <1% | 148 | $25K | |
| 95819 | <1% | 177 | $25K | |
| 86618 | <1% | 746 | $25K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,269 | $25K |
| 84156 | <1% | 627 | $24K | |
| 85384 | <1% | 901 | $23K | |
| 77075 | <1% | 179 | $22K | |
| A9150 | Non-prescription drugs | <1% | 9,411 | $22K |
| 82962 | <1% | 3,233 | $22K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,487 | $21K |
| 81479 | Unlisted molecular pathology procedure | <1% | 412 | $21K |
| 86364 | <1% | 237 | $21K | |
| 80306 | <1% | 813 | $20K | |
| 92585 | <1% | 146 | $20K | |
| 85660 | <1% | 1,111 | $19K | |
| 12001 | <1% | 258 | $18K | |
| 90686 | <1% | 1,455 | $18K | |
| 82803 | <1% | 420 | $18K | |
| 84703 | <1% | 927 | $18K | |
| 94644 | <1% | 137 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,879 | $17K |
| 87481 | <1% | 333 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,488 | $16K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 7,349 | $16K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 133 | $16K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,121 | $16K |
| 82150 | <1% | 843 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 852 | $16K |
| 76825 | <1% | 157 | $15K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,524 | $15K |
| 87486 | <1% | 2,388 | $15K | |
| 93017 | <1% | 43 | $14K | |
| 82550 | <1% | 702 | $14K | |
| 87581 | <1% | 2,386 | $14K | |
| 86923 | <1% | 317 | $13K | |
| 88304 | <1% | 377 | $13K | |
| 73030 | <1% | 163 | $12K | |
| 83655 | <1% | 1,676 | $12K | |
| 87507 | <1% | 142 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,507 | $12K |
| 74181 | <1% | 27 | $12K | |
| 83930 | <1% | 251 | $12K | |
| 92593 | <1% | 111 | $12K | |
| 99157 | <1% | 190 | $11K | |
| 84403 | <1% | 427 | $11K | |
| 97165 | <1% | 74 | $11K | |
| 72195 | <1% | 13 | $11K | |
| 73000 | <1% | 106 | $11K | |
| 86592 | <1% | 1,190 | $11K | |
| 83002 | <1% | 459 | $10K | |
| 87641 | <1% | 645 | $9K | |
| 81229 | <1% | 149 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,064 | $9K |
| 51741 | <1% | 168 | $9K | |
| 96450 | <1% | 40 | $9K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 5,718 | $9K |
| 84480 | <1% | 679 | $8K | |
| 86039 | <1% | 182 | $8K | |
| 51798 | <1% | 342 | $8K | |
| 80299 | <1% | 78 | $8K | |
| 76827 | <1% | 157 | $8K | |
| 87081 | <1% | 3,007 | $8K | |
| 72081 | <1% | 223 | $8K | |
| 84436 | <1% | 466 | $8K | |
| 94770 | <1% | 479 | $8K | |
| 73070 | <1% | 92 | $7K | |
| 83525 | <1% | 372 | $7K | |
| 92652 | <1% | 29 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,067 | $7K |
| 94645 | <1% | 25 | $7K | |
| 85027 | <1% | 849 | $6K | |
| 96376 | <1% | 161 | $6K | |
| 82310 | <1% | 470 | $6K | |
| 82670 | <1% | 205 | $6K | |
| 83001 | <1% | 376 | $6K | |
| 82652 | <1% | 883 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,062 | $5K |
| 86803 | <1% | 385 | $5K | |
| 73564 | <1% | 167 | $5K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 620 | $5K |
| 86480 | <1% | 164 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,947 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,019 | $5K |
| 82947 | <1% | 400 | $4K | |
| 87512 | <1% | 317 | $4K | |
| 84484 | <1% | 61 | $4K | |
| 84460 | <1% | 509 | $4K | |
| 87102 | <1% | 301 | $4K | |
| 86160 | <1% | 100 | $4K | |
| 82610 | <1% | 203 | $4K | |
| 74455 | <1% | 34 | $3K | |
| 97167 | <1% | 12 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,894 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,132 | $3K |
| 87640 | <1% | 51 | $3K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 3,167 | $3K |
| 83615 | <1% | 122 | $3K | |
| 80069 | <1% | 56 | $3K | |
| 88312 | <1% | 181 | $3K | |
| 84450 | <1% | 419 | $3K | |
| 29130 | <1% | 32 | $3K | |
| 84157 | <1% | 164 | $3K | |
| 89050 | <1% | 93 | $3K | |
| 73620 | <1% | 42 | $3K | |
| 73060 | <1% | 48 | $3K | |
| 86376 | <1% | 164 | $2K | |
| 72040 | <1% | 117 | $2K | |
| 76882 | <1% | 64 | $2K | |
| 83520 | <1% | 95 | $2K | |
| 95951 | <1% | 61 | $2K | |
| 82945 | <1% | 95 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,767 | $2K |
| 95700 | <1% | 14 | $2K | |
| 36591 | <1% | 240 | $2K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,540 | $2K |
| 86665 | <1% | 352 | $2K | |
| 92595 | <1% | 24 | $2K | |
| 97760 | <1% | 60 | $2K | |
| 86359 | <1% | 179 | $2K | |
| 73100 | <1% | 12 | $2K | |
| 84305 | <1% | 235 | $2K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 12 | $2K |
| 85246 | <1% | 32 | $2K | |
| 85397 | <1% | 14 | $2K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 644 | $2K |
| 86255 | <1% | 64 | $2K | |
| 69210 | <1% | 143 | $2K | |
| 85240 | <1% | 34 | $1K | |
| 83498 | <1% | 13 | $1K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 14 | $1K |
| 80329 | <1% | 14 | $1K | |
| 87205 | <1% | 1,625 | $1K | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 1,931 | $1K |
| 85018 | <1% | 441 | $1K | |
| 80074 | <1% | 32 | $1K | |
| 81025 | <1% | 34 | $1K | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 46 | $1K |
| 84466 | <1% | 121 | $984.51 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,588 | $973.17 |
| 86317 | <1% | 105 | $958.53 | |
| 86225 | <1% | 15 | $913.48 | |
| 86921 | <1% | 175 | $897.17 | |
| 87800 | <1% | 211 | $877.07 | |
| 90656 | <1% | 101 | $839.35 | |
| 86706 | <1% | 358 | $823.66 | |
| 80164 | <1% | 138 | $802.80 | |
| 84550 | <1% | 31 | $734.42 | |
| 86360 | <1% | 34 | $715.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 245 | $671.15 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 563 | $657.44 |
| 82247 | <1% | 308 | $555.42 | |
| 82043 | <1% | 70 | $505.76 | |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 14 | $491.72 |
| 51600 | <1% | 35 | $479.57 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 201 | $468.74 |
| 87147 | <1% | 73 | $405.25 | |
| 82248 | <1% | 266 | $398.51 | |
| 86664 | <1% | 224 | $391.12 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 477 | $384.23 |
| 86357 | <1% | 81 | $345.35 | |
| 86355 | <1% | 81 | $345.35 | |
| 86800 | <1% | 13 | $320.76 | |
| 86308 | <1% | 271 | $307.26 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 254 | $304.96 |
| 84146 | <1% | 116 | $297.67 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 92 | $296.13 |
| V5266 | Battery for use in hearing device | <1% | 12 | $295.15 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 113 | $265.32 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 322 | $262.11 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 70 | $232.33 |
| 85044 | <1% | 633 | $194.21 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $171.20 |
| 84402 | <1% | 16 | $137.43 | |
| 86708 | <1% | 19 | $134.82 | |
| 94729 | <1% | 45 | $132.99 | |
| 82607 | <1% | 30 | $129.36 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 28 | $129.20 |
| 86663 | <1% | 83 | $65.07 | |
| 86885 | <1% | 113 | $56.96 | |
| 87340 | <1% | 220 | $45.90 | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 42 | $37.49 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 59 | $32.76 |
| 88300 | <1% | 18 | $31.83 | |
| 86704 | <1% | 123 | $28.86 | |
| 85060 | <1% | 13 | $25.45 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 13 | $25.30 |
| 85014 | <1% | 71 | $19.14 | |
| 80177 | <1% | 32 | $14.44 | |
| 78264 | 0% | 45 | $0.00 | |
| 84134 | 0% | 20 | $0.00 | |
| 73660 | 0% | 12 | $0.00 | |
| 97113 | 0% | 27 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 17 | $0.00 |
| 93886 | 0% | 13 | $0.00 | |
| 83021 | 0% | 30 | $0.00 | |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 28 | $0.00 |
| 74230 | 0% | 16 | $0.00 | |
| 92611 | 0% | 17 | $0.00 | |
| 78262 | 0% | 30 | $0.00 | |
| 94726 | 0% | 28 | $0.00 | |
| 84630 | 0% | 15 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 45 | $0.00 |
| 72100 | 0% | 38 | $0.00 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 0% | 17 | $0.00 |
| 86235 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUMFORD, MARK (EVP, COO)
Parent organizationTHE NEMOURS FOUNDATION
| Provider | Location | Paid |
|---|---|---|
| The Nemours Foundation | Wilmington, DE | $172.06M |
| The Nemours Foundation | Philadelphia, PA | $5.85M |
| Nemours New Jersey Physician Practice, P.C. | Deptford, NJ | $1.45M |
| The Nemours Foundation | Deptford, NJ | $97K |
| The Nemours Foundation | Wilmington, DE | $65K |
| The Nemours Foundation | Wilmington, DE | $22K |
| The Nemours Foundation | Wilmington, DE | $6K |
| The Nemours Foundation | New Castle, DE | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.